Clinical Trials Browser

Blood Protein Disorders, Bone Diseases, Bone Marrow Diseases, Bone Neoplasms, Hematologic Diseases, Multiple Myeloma, Neoplasm Metastasis, Neoplasms, Neoplastic Processes, Paraproteinemias, Spinal Cord Compression, Hematologic Neoplasms, Fractures, Bone, Neoplasms, Plasma Cell

NCT00381095 2021-01-20

COPE

Phase 4 Terminated

152 enrolled 14 charts

Sarcoma

Bone Neoplasms, Neoplasms, Pain, Intractable

NCT00981578 2020-03-11

ExAblate Conformal Bone System Treatment of Metastatic Bone Tumors for the Palliation of Pain

Phase NA Terminated

37 enrolled 10 charts

BreastGenitourinarySarcomaThoracic

Cancer Pain, Bone Neoplasms, Breast Neoplasms, Lung Neoplasms, Neoplasm Metastasis, Neoplasms, Prostatic Neoplasms

NCT00656305 2020-02-05

ExAblate (MRgFUS) Treatment of Metastatic Bone Tumors for the Palliation of Pain

Phase NA Completed

147 enrolled 12 charts

BreastGenitourinaryPlasma cellSarcomaThoracic

Cancer Pain, Bone Neoplasms, Breast Neoplasms, Lung Neoplasms, Multiple Myeloma, Neoplasm Metastasis, Neoplasms, Prostatic Neoplasms

NCT00960063 2018-08-27

A Study of Robatumumab (SCH 717454, MK-7454) in Combination With Different Treatment Regimens in Pediatric Participants With Advanced Solid Tumors (P05883, MK-7454-006)

Phase 1 Terminated

4 enrolled 8 charts

CNSGenitourinarySarcoma

Bone Neoplasms, Carcinoma, Renal Cell, Neoplasms, Neuroblastoma

Clinical Trials

EPIBONE

A Phase I Trial to Assess the Effects of Food and Formulation on PK of KPT-330 in Patients With Sarcoma

Study to Evaluate the Safety and Activity (Including Distribution) of 177Lu-3BP-227 in Subjects With Solid Tumours Expressing Neurotensin Receptor Type 1.

BIOGUIDE-X

Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Patients With Multiple Myeloma

COPE

ExAblate Conformal Bone System Treatment of Metastatic Bone Tumors for the Palliation of Pain

ExAblate (MRgFUS) Treatment of Metastatic Bone Tumors for the Palliation of Pain

A Study of Robatumumab (SCH 717454, MK-7454) in Combination With Different Treatment Regimens in Pediatric Participants With Advanced Solid Tumors (P05883, MK-7454-006)